Lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-22 and is reviewed periodically as new material appears.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
== Further reading == Fetter, Steve; Cheng, E. T.; Mann, F. M. (1990). "Long-term radioactive waste from fusion reactors: Part II". Fusion Engineering and Design. 13 (2): 239–246. CiteSeerX 10.1.1.465.5945. doi:10.1016/0920-3796(90)90104-E. ISSN 0920-3796. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) Holland, Jason P.; Sheh, Yiauchung; Lewis, Jason S. (2009). "Standardized methods for the production of high specific-activity zirconium-89". Nuclear Medicine and Biology. 36 (7): 729–739. doi:10.1016/j.nucmedbio.2009.05.007. ISSN 0969-8051. PMC 2827875. PMID 19720285. McCarthy, Deborah W.; Shefer, Ruth E.; Klinkowstein, Robert E.; Bass, Laura A.; Margeneau, William H.; Cutler, Cathy S.; Anderson, Carolyn J.; Welch, Michael J. (1997). "Efficient production of high specific activity 64Cu using a biomedical cyclotron". Nuclear Medicine and Biology. 24 (1): 35–43. doi:10.1016/S0969-8051(96)00157-6. ISSN 0969-8051. PMID 9080473.
Nonetheless, some genes may have helped modern East Asians adapt to the environment; the putatively Neanderthal Val92Met variant of the MC1R gene, which may be weakly associated with red hair and UV radiation sensitivity, is primarily found in East Asian, rather than European, individuals. Some genes related to the immune system appear to have been affected by introgression, which may have aided migration, such as OAS1, STAT2, TLR6, TLR1, TLR10, and several related to immune response. In addition, Neanderthal genes have also been implicated in the structure and function of the brain, keratin filaments, sugar metabolism, muscle contraction, body fat distribution, enamel thickness and oocyte meiosis. Nonetheless, a large portion of surviving introgression appears to be non-coding ("junk") DNA with few biological functions. A 2016 study indicated that human-Neanderthal gene variance may be involved in autism, with chromosome 16 section 16p11.2 deletions playing a large role. A 2017 study reported finding that the more Neanderthal DNA a person has in their genome, the more closely the brain of the individual would resemble that of a Neanderthal. The study also found that parts of the Neanderthal brain related to tool use and visual discrimination may have also experienced evolutionary or adaptational "trade-offs" with the "social brain", as also found in scientific studies on autism.
=== Domestic politics === On the outbreak of war, Huggins invited the leader of the opposition Labour Party, Harry Davies, to join a coalition government. Davies accepted without consulting his party caucus, much to the indignation of many of his contemporaries; Labour promptly split. The two Labour factions reconciled in 1943 and briefly threatened Huggins's premiership until a heated dispute over whether Labour should become multiracial led to the party's disintegration in 1944.
=== Mortars === Two-inch mortar – Fielded until the 1980s ML 3-inch mortar – in service through to the 1960s L16 81mm mortar – Main Cold War mortar. ML 4.2-inch mortar – saw service in 1960s L10A1 51mm mortar – Introduced in the 1980s
Sources: en.wikipedia.org
The Bergmann azlactone peptide synthesis is a classic organic synthesis process for the preparation of dipeptides. In the presence of a base, peptides are formed by aminolysis of N-carboxyanhydrides of amino acids with amino acid esters (1). This reaction can be looked at in further detail by Bailey. The resulting peptide is then protected by esters of benzylchroroformate in order to keep the amino groups intact (2). This mechanism serves as a source of protection for the amino group in the amino acid. The ester will block the amino group from binding with other molecules. The last step in this reaction is the cyclization of the N-haloacylamino acids with an acetanhydride. This will result in the expected azlactone (3). The reaction with a second amino acid allows for the ring to open, later forming an acylated unsaturated dipeptide. The reaction happens in a step-wise function which allows for the amino group to be protected and the azlactone to be produced. Catalytic hydrogenation and hydrolysis then take place in order to produce the dipeptide (4).
Thorium (90Th) has seven naturally occurring isotopes but none are stable. One isotope, 232Th, is relatively stable, with a half-life of 1.40×1010 years, considerably longer than the age of the Earth, and even slightly longer than the generally accepted age of the universe. This isotope makes up nearly all natural thorium, so thorium was considered to be mononuclidic. However, in 2013, IUPAC reclassified thorium as binuclidic, due to large amounts of 230Th in deep seawater. Thorium has a characteristic terrestrial isotopic composition and thus a standard atomic weight can be given. Thirty-one radioisotopes have been characterized, with the most stable being 232Th, 230Th with a half-life of 75,400 years, 229Th with a half-life of 7,916 years, and 228Th with a half-life of 1.91 years. All of the remaining radioactive isotopes have half-lives that are less than thirty days and the majority of these have half-lives that are less than ten minutes. One isotope, 229Th, has a nuclear isomer (or metastable state) with a remarkably low excitation energy, recently measured to be 8.355733554021(8) eV It has been proposed to perform laser spectroscopy of the 229Th nucleus and use the low-energy transition for the development of a nuclear clock of extremely high accuracy. The known isotopes of thorium range in mass number from 207 to 238.
== Adverse effects == In individuals already taking sulphonylureas, use of DPP-4-class medications concurrently increases their risk for low blood sugar events relative to those on sulphonylureas alone. Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity, and skin reactions. In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling. However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive. A 2014 review found that the use of saxagliptin and alogliptin increased individuals' risk of developing heart failure, leading the FDA to add warnings to the labels of these drugs in 2016. A 2018 meta-analysis indicated that the use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared to placebo or no treatment. Additionally, a 2018 observational study suggested an elevated risk of developing inflammatory bowel disease, specifically ulcerative colitis, which peaked after three to four years of use and decreased after more than four years. Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes.
Sources: en.wikipedia.org
=== In French === Sylvie Aprile, La Deuxième République et le Second Empire, Pygmalion, 2000 Choisel, Francis, La Deuxième République et le Second Empire au jour le jour, chronologie érudite détaillée, Paris, CNRS Editions, 2015. Inès Murat, La Deuxième République, Paris: Fayard, 1987 Philippe Vigier, La Seconde République, (series Que sais-je?) Paris: Presses Universitaires de France, 1967
9 August – A second Police Service of Northern Ireland data breach is revealed after it emerges a spreadsheet containing the names of 200 officers was stolen from a car in July 2023. 10 August High street bargain homeware retailer Wilko goes into administration. The move puts 12,000 jobs across 400 shops at risk. Simon Byrne, the Chief Constable of the Police Service of Northern Ireland, says he is "deeply sorry" about two "industrial scale" data breaches, but will not resign over the controversy. Coronation of Charles III and Camilla: The Royal Mint unveils a special official Coronation 50 pence coin. 11 August Data from the Office for National Statistics shows the UK economy grew by an average 0.2% between April and June 2023. This includes a better than expected increase of 0.5% for June as a result of warm weather which boosted both the construction and hospitality industries. Migrants are temporarily moved from the Bibby Stockholm after traces of the Legionella bacteria are found in the water supply. The number of migrants who have crossed the English Channel since 2018 passes 100,000. 12 August England captain Harry Kane joins German champions Bayern Munich on a four-year deal, ending his record-breaking career at Tottenham Hotspur. Six people are killed and 58 rescued by British and French coastguards after a boat carrying migrants sinks off the French coast, near Sangatte, in the English Channel. 14 August – Health Secretary Steve Barclay confirms "no-one has been harmed" following the discovery of legionella bacteria on the Bibby Stockholm.
=== Proteogenomics === In proteogenomics, proteomic technologies such as mass spectrometry are used for improving gene annotations. Parallel analysis of the genome and the proteome facilitates discovery of post-translational modifications and proteolytic events, especially when comparing multiple species (comparative proteogenomics).
==== X-ray passport ==== Since 2002, an x-ray pass is a document in which the examining physician or dentist must enter information about the x-ray examinations performed on the patient. The main aim was to avoid unnecessary repeat examinations. According to the new Radiation Protection Ordinance (StrlSchV), practices and clinics are no longer obliged to offer their patients X-ray passports and to enter examinations in them. The Radiation Protection Ordinance came into force on December 31, 2018, together with the Radiation Protection Act (StrlSchG) passed in 2017, replacing the previous Radiation Protection Ordinance and the X-ray Ordinance. The Federal Office for Radiation Protection (BfS) continues to advise patients to keep records of their own radiation diagnostic examinations. On its website, the BfS provides a downloadable document that can be used for personal documentation.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.